Advisory committee recommends FDA approve first RSV vaccines for older Americans 

A Food and Drug Administration advisory committee this week recommended the agency approve the first two vaccines to prevent lower respiratory tract disease caused by respiratory syncytial virus in Americans aged 60 and older. In separate votes Feb. 28 and March 1, a majority of committee members said available data support the safety and effectiveness of the two vaccine candidates, made by Pfizer and GSK. The FDA will now consider whether to approve the vaccines for use in this age group.